Anti-HMW Cytokeratin antibody [34bE12] (ab776)
Key features and details
- Mouse monoclonal [34bE12] to HMW Cytokeratin
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-HMW Cytokeratin antibody [34bE12] -
Description
Mouse monoclonal [34bE12] to HMW Cytokeratin -
Host species
Mouse -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human HMW Cytokeratin. Solubilized keratin extract from human stratum corneum.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.3
Preservative: 0.05% Sodium azide
Constituents: Tissue culture supernatant, 1% BSA -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
34bE12 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab776 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/25 - 1/50.
Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation conditions and antibody dilutions should be determined by the user. Enzymatic antigen retrieval of paraffin embedded tissues is recommended prior to immunostaining. |
Notes |
---|
IHC-P
1/25 - 1/50. Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation conditions and antibody dilutions should be determined by the user. Enzymatic antigen retrieval of paraffin embedded tissues is recommended prior to immunostaining. |
Target
-
Relevance
Cytokeratins are intermediate filament keratins found in the intracytoplasmic cytoskeleton of epithelial tissue. There are two types of Cytokeratins: the low weight, acidic type I cytokeratins and the high weight, basic or neutral type II. Cytokeratins are usually found in pairs comprising a type I Cytokeratin and a type II cytokeratin. The high molecular weight cytokeratins, which are the basic or neutral cytokeratins, comprise subtypes CK1 (67), CK2 (65.5), CK3 (64), CK4 (59), CK5 (58), CK6 (56), CK7 (54), CK8 (52.5) and CK9. The low molecular weight cytokeratins, which are the acidic cytokeratins, comprise subtypes CK10 (56.5), CK12 (56), CK13 (53), CK14 (50), CK16( 48), CK17 (46), CK18 (45), CK19(48) and CK20(46). -
Cellular localization
Cytoplasmic -
Database links
- Entrez Gene: 3860 Human
- Entrez Gene: 3861 Human
- Entrez Gene: 3866 Human
- Entrez Gene: 3868 Human
- Omim: 148030 Human
- Omim: 148065 Human
- Omim: 148066 Human
- Omim: 148067 Human
see all -
Alternative names
- CK13 antibody
- CK14 antibody
- CK15 antibody
see all
Images
Datasheets and documents
-
Datasheet download
References (2)
ab776 has been referenced in 2 publications.
- Hermanova I et al. Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. J Exp Med 217:N/A (2020). PubMed: 32219437
- Hagman Z et al. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108:1668-76 (2013). IHC ; Human . PubMed: 23571738